<DOC>
	<DOCNO>NCT00301106</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use gene-modified virus make interleukin-12 may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose gene-modified virus make interleukin-12 treating woman breast cancer spread liver .</brief_summary>
	<brief_title>Biological Therapy Treating Women With Breast Cancer That Has Spread Liver</brief_title>
	<detailed_description>Direct intratumoral injection metastatic hepatic tumor use adenoviral vector express human recombinant interleukin-12 gene ( Adv.RSV-hIL12 , also term ADV-hIL-12 ) . OBJECTIVES : - Study toxicity escalate dos adenoviral vector express human recombinant interleukin-12 gene , administer percutaneous intratumoral injection , woman liver metastasis secondary breast cancer . - Determine tumor response produce regimen . - Determine immune response induce regimen .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirmed* breast adenocarcinoma metastatic liver Solitary multiple hepatic metastases No malignant involvement &gt; 40 % estimate liver volume NOTE : *Must hepatic tumor designate study injection Metastatic liver tumor must measurable ≥ 2 dimension CT scan MRI At least 1 metastatic hepatic tumor ≥ 2 cm diameter must visualize ultrasound accessible percutaneous injection ultrasound guidance Extrahepatic metastasis allow No solitary hepatic metastasis eligible liver resection No clinical evidence severe liver disease ( e.g. , prior current ascites portosystemic encephalopathy ) Hormonereceptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify Granulocyte count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 PT ≤ 14.5 sec Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 45 mL/min Bilirubin ≤ 2 time upper limit normal ( ULN ) Transaminases ≤ 2.5 time ULN Karnofsky performance status ≥ 70 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 2 month completion study treatment No active infection serious intercurrent medical illness No HIV infection Life expectancy ≥ 16 week No malignancy within past 5 year except inactive nonmelanoma skin cancer , situ carcinoma cervix , grade 1 papillary bladder cancer At high dose level , patient must weigh ≥ 30 kg PRIOR CONCURRENT THERAPY : No systemic immunosuppressive drug , include corticosteroid , within 2 month prior study entry Not require immunosuppressive drug anticoagulant therapy heparin warfarin least 2 month study treatment No chemotherapy within 4 week study entry ( 6 week nitrosoureas )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>